高压纳秒脉冲电场杀伤化疗抗性肿瘤细胞的实验机理研究

doi:10.3969/j.issn.0258-8021.2019.03.010

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (3550 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Tumor seriously endanger the lives and health of human people. Chemoresistance is one of the main barriers to successful tumor treatment. In order to explore whether high voltage nanosecond pulsed electric fields can be equally sensitive to chemotherapy-resistant tumor cells compared with its homology tumor cells, lung cancer cell line A549 and cisplatin chemotherapy-resistant A549/R were used as the research object in this paper. After exposing to the 80 nanosecond pulses with a pulse width of 200 ns and a field strength of 5-15 kV/cm, the activity of cell, apoptosis and necrosis and ablation effect were analyzed and compared in groups. The results showed that the survival rate of A549/R was 5.65%, 7.78% and 2.80% respectively when exposed topulses electric field with strength of 8kV/cm, 10 kV/cm and 15 kV/cm, which was significantly lower than that of A549 cells (48.31%, 26.8%, and 5.96%, respectively for 8 kV/cm, 10 and 15 kV/cm). The induced apoptosis and necrosis rates were also significantly higher than A549 (P<0.05); In addition, when exposed to 80 pulses(200 ns, 15 kV/cm), the ablation area of single-layer cells for A549/R was 1.59 times that of A549 cells, and the ablation threshold for A549/R (8 kV/cm) is significantly lower than that of A549 (13 kV/cm). Therefore, the nanosecond pulsed electric field with a pulse width of 200 ns could preferentially kill A549/R, inducing a higher rate of apoptosis, ablation area and a lower ablation threshold. The experimental results showed that high-voltage nanosecond pulse could preferentially act on chemotherapy-resistant tumor cells.

Key words： Nanosecond pulse chemoresistance electroporation tumor treatment targeted ablation

Received: 28 August 2018

PACS:

R318

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Liu Hongmei
	Wang Li
	Dong Shoulong
	Ma Jianhao
	Wang Yilin
	Yao Chenguo

Cite this article:

Liu Hongmei,Wang Li,Dong Shoulong, et al. Experimental Mechanism Study on Killing of Chemoresistant Tumor Cells Exposed to High Voltage Nanosecond Pulse Field[J]. Chinese Journal of Biomedical Engineering, 2019, 38(3): 332-338.

URL:

http://cjbme.csbme.org/EN/10.3969/j.issn.0258-8021.2019.03.010 OR http://cjbme.csbme.org/EN/Y2019/V38/I3/332

[1] Chen W, Zheng R, Baade PD, et al., Cancer statistics in China,2015 [J]. CA: A Cancer Journal for Clinicians, 2016, 66(2):115-132.
[2] Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising [J]. International Journal of Cancer, 2010, 117(2):294-299.
[3] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. The Journal of Evidence-Based Medicine, 2009, 361(10):947-957.
[4] Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy [J]. Cancer Research, 1995, 55(21):4760-4764.
[5] Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: The role of DNA repair pathways [J]. Clinical Cancer Research, 2008, 14(5):1291-1295.
[6] Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance [J]. Oncogene, 2003, 22(47):7369-7375.
[7] Oza AM. Clinical development of P glycoprotein modulators in oncology [J]. Novartis Foundation Symposium, 2002, 243(1):103-115.
[8] Solyanik G. Multifactorial nature of tumor drug resistance [J]. Experimental Oncology, 2010, 32(3):181-185.
[9] Zhang R, Yao W, Qian P, et al. Increased sensitivity of human lung adenocarcinoma cells to cisplatin associated with downregulated contactin-1 [J]. Biomedicine & Pharmacotherapy, 2015, 71(1):172-184.
[10] Miklavcˇicˇ D, Serš a G, Brecelj E, et al. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors [J]. Medical & Biological Engineering & Computing, 2012, 50(12):1213-1225.
[11] Beebe SJ, Sain NM, Ren W. Induction of cell death mechanisms and apoptosis by nanosecond pulsed electric fields (nsPEFs) [J]. Cells, 2013, 2(1):136-162.
[12] Schoenbach KH, Beebe SJ, Buescher ES. Intracellular effect of ultrashort electrical pulses [J]. Bioelectromagnetics, 2001, 22(6):440-448.
[13] Schoenbach KH, Joshi RP, Kolb JF, et al. Ultrashort electrical pulses open a new gateway into biological cells [J]. Proceedings of the IEEE, 2004, 92(7):1122-1137.
[14] 姚陈果,孙才新,米彦,等. 陡脉冲不可逆性电击穿治疗肿瘤的研究 [J]. 高电压技术, 2007, 33(2):7-13.
[15] Nuccitelli R, Huynh J, Lui K, et al. Nanoelectroablation of human pancreatic carcinoma in a murine xenograft model without recurrence [J]. International Journal of Cancer, 2013, 132(8):1933-1939.
[16] Nuccitelli R, Berridge JC, Mallon Z, et al. Nanoelectroablation of murine tumors triggers a CD8-dependent inhibition of secondary tumor growth [J]. PLoS ONE, 2015, 10(7):e0134364.
[17] Nuccitelli R, Mcdaniel A, Anand S, et al. Nano-pulse stimulation is a physical modality that can trigger immunogenic tumor cell death [J]. Journal for Immunotherapy of Cancer, 2017, 5(1):32.
[18] Yao C, Hu X, Mi Y, et al. Window effect of pulsed electric field on biological cells [J]. IEEE Transactions on Dielectrics & Electrical Insulation, 2009, 16(5):1259-1266.
[19] Ivey JW, Latouche EL, Sano MB, et al. Targeted cellular ablation based on the morphology of malignant cells [J]. Scientific Reports, 2015, 5(1):17157.